Absci Corporation (Nasdaq: ABSI) announced details of its planned Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE